ERK Inhibitor JSI-1187 in Advanced Solid Tumors
NCT06239623
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
NSCLC
Melanoma
Interventions
DRUG:
JSI-1187
Sponsor
JS InnoPharm, LLC